First US Generic Adempas
Zydus and MSN launch the first US generic version of Adempas for pulmonary hypertension.
Anonymous
Zydus Lifesciences and MSN Laboratories have launched the first U.S. generic version of Adempas (riociguat), FDA-approved in five strengths for adults with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. MSN developed and manufactures the tablets, while Zydus brings its U.S. commercial reach; the companies say the launch can expand access with a generic alternative to the previously branded-only treatment. The launch may affect market pricing and access, though the sources provide no specific generic price or sales outlook.
Key Points
1
Bayer reported global Adempas sales of about €745 million in 2025, equivalent to roughly US$850 million, offering a measure of the branded drug’s existing market.
2
The articles describe PAH and CTEPH as rare, progressive conditions that can be life-threatening and may require patients to remain on therapy for life.
3
For CTEPH, the approved use specifically includes persistent or recurrent disease after surgical treatment as well as inoperable disease; the treatment aims to improve exercise capacity and WHO functional class.
4
MSN founder and CMD Dr. MSN Reddy called riociguat a technically demanding molecule and said the partnership aims to deliver a consistent, high-quality supply.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
14
Articles
17
Reach
31
Topics
A
AnonymousAuthor
